Cytokine Profiles as Biomarkers for Neurodegenerative Diseases: An inflammatory study on Parkinson’s Disease and Tauopathies
Objective: To investigate the diagnostic and prognostic value of cytokine profiles in cerebrospinal fluid (CSF) and serum of patients with Parkinson's Disease (PD), Progressive Supranuclear…18F-Florzolotau PET uncovers the Co-pathological Heterogeneity of Tau Protein in Dementia with Lewy Bodies
Objective: We attempted to reveal the topographical deposition patterns of tau proteins in the living brains of patients with DLB in vivo by virtue of…Case Report: An Unusual Case of Corticobasal Syndrome
Objective: To describe a patient with corticobasal syndrome (CBS) and biomarker evidence of multiple proteinopathies. Background: CBS is a clinically heterogeneous syndrome caused by several…A Visual Interpretation Algorithm for Assessing 18F-Florzolotau PET Scans in Progressive Supranuclear Palsy
Objective: This study aimed to develop a visual reading algorithm dedicated to the evaluation of 18F-Florzolotau positron emission tomography (PET) scans in PSP. Background: The…18F-Florzolotau PET imaging of tau pathology in the living brain of patients with corticobasal syndrome
Objective: To analyze the topographical patterns of tau pathology in the living brains of patients with CBS using 18F-Florzolotau PET imaging and to examine whether…Neurofilament light chain, tau-PET and microglia-PET predict clinical progression in amyloid-negative corticobasal syndrome
Objective: A head-to-head comparison of neuroimaging (tau-PET, microglia-PET, structural MRI) and plasma biomarker Neurofilament light chain (NfL) as prognostic tools for longitudinal clinical trajectories in…The monoamine oxidase-B inhibitor selegiline does not affect 18F-Florzolotau uptake in patients with progressive supranuclear palsy: a longitudinal case series
Objective: In a longitudinal case series of patients with progressive supranuclear palsy (PSP), a chronic challenge with the irreversible MAO-B inhibitor selegiline was used to…Evaluation of a novel Phosphodiesterase 5 inhibitor as a potential therapeutic agent in P301S transgenic mouse model of tauopathy.
Objective: In the current study, we evaluated a newly developed compound with a 1,3,5-trisubstituted pyrazoline scaffold with an improved PDE5 inhibitory potency as a potential…A tau-directed monoclonal antibody could alter the tau pathology of progressive supranuclear palsy
Objective: The purpose of this study is to examine the modification of tau pathology in brain regions of a patient with progressive supranuclear palsy (PSP)…Investigate the association of MAPT haplotype and neuroanatomical structure and its influence on the risk of Parkinson’s disease
Objective: To investigate if the vulnerability of Parkinson’s Disease (PD) can be reflected in the neuroanatomical structure in different MAPT haplotype carriers. Background: It has…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 14
- Next Page »